ASX Announcement **17 April 2026**

BlinkLab Invited to Present at Ignite Investment Summits in Hong Kong and Singapore

Highlights:

- **BlinkLab invited to present at the Ignite Investment Summit in Hong Kong (15-16 April 2026) and Singapore (21-22 April 2026).**
- **This follows a successful capital raise of A$17.7 million (before costs) following firm commitments from domestic and international, Institutional and Sophisticated Investors.**

BlinkLab Limited (ASX:BB1) ("BlinkLab" or the "Company"), a leading digital healthcare company focused on the development of AI-powered diagnostic technology, is pleased to announce that the Company was invited to attend the **Ignite Investment Summit** events in both **Hong Kong (15-16 April 2026)** and **Singapore (21-22 April 2026)**.

BlinkLab, having already attended the Hong Kong event, will be presenting in Singapore next week as a part of BlinkLab's ongoing engagement with professional and sophisticated investors throughout the Asia-Pacific region where the Company has strong existing investor relationships.

The Company looks forward to next week's event in Singapore where Mr Brian Leedman (BlinkLab's Chairman), has been invited to present as part of a panel at the prestigious event, while Dr Henk-Jan Boele (BlinkLab's Co-Founder, CEO, and Managing Director), will be taking part in the events' CEO presentations. The BlinkLab management team will also be present as exhibitors.

Ignite Investment Summit – Singapore
Dates: 21-22 April 2026
Venue: The Fullerton Hotel, 1 Fullerton Square, Singapore 049178
Registration: https://weareignite.com/events/singapore-april-2026/

The Ignite Investment Summit events offer opportunities for BlinkLab to connect with professional and sophisticated investors throughout the region via the company presentations, as well as one-on-one meetings and further follow-up meetings surrounding the conference's proceedings.

The international engagements in both Hong Kong and Singapore follows BlinkLab's recent successful capital raise of ~A$17.7 million (before costs) and placement of new ordinary shares anticipated to be

completed next week (the "Placement") to institutional, sophisticated, and professional investors, announced 16 April 2026 (director allocations subject to shareholder approval).[1]

A copy of the Company's latest investor presentation is attached below this announcement.

This announcement has been approved by the Board of Directors.

For further information please contact:

Dr Henk-Jan Boele
CEO and Managing Director
henkjan@blinklab.org
+31 (0) 611 132 247

Mr Brian Leedman
Non-Executive Chairman
brian@blinklab.org
+61 (0) 412 281 780

About BlinkLab Limited (ASX:BB1)

BlinkLab Limited, a company founded by neuroscientists at Princeton University, over the past several years has fully developed a smartphone based diagnostic platform for autism, ADHD, schizophrenia, and other neurodevelopmental conditions. Our most advanced product is an autism diagnostic test that leverages the power of smartphones, AI and machine learning to deliver screening tests specifically designed for children as young as 18 months old. This marks a significant advancement, considering traditional diagnoses typically occur around five years of age, often missing the crucial early window for effective intervention. BlinkLab is led by an experienced management team and directors with a proven track record in building companies and vast knowledge in digital healthcare, computer vision, AI and machine learning. Our Scientific Advisory Board consists of leading experts in the field of autism and brain development allowing us to bridge most advanced technological innovations with groundbreaking scientific research.

[1] ASX Announcement (16 April 2026)

blinklab *(ASX:BB1)*

Early and Accurate Diagnosis of Autism and ADHD

Introducing an AI-powered smartphone platform for neurometric testing

April 2026, BlinkLab Ltd
Ignite Investment Summit – Hong Kong, Singapore

Disclaimer

This presentation has been prepared by BlinkLab Limited (ACN 652 901 703) (**BlinkLab** or **Company**) and contains background information about BlinkLab's current operations at the date of this presentation. The presentation is in summary form and does not purport to be all inclusive or complete.

Recipients should conduct their own investigations and perform their own analysis in order to satisfy themselves as to the accuracy and completeness of the information, statements and opinions contained in this presentation. This presentation is for information purposes only. Neither this presentation nor the information contained in it constitutes an offer, invitation, solicitation or recommendation in relation to the purchase or sales of shares or other securities in any jurisdiction. This presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with the Australian Securities and Investments Commission) or any other law.

This presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) and has been prepared without taking into account the recipient's investment objectives, financial circumstances or particular needs and the opinions and recommendations in this presentation are not intended to represent recommendations of particular investments to particular persons. Recipients should seek professional advice when deciding if an investment is appropriate. All securities involve risks which include (among others) the risk of adverse or unanticipated market, financial or political developments.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions which are outside the control of BlinkLab. Actual results or events may be materially different to those expressed or implied in this presentation. Given these uncertainties, recipients are cautioned not to place reliance on forward looking statements.

Corporate Snapshot

blinklab

CAPITAL STRUCTURE - ASX:BB1	
Shares on Issue	**153.1M**
Options on Issue	**49.7M**
Performance Rights	**4.4M**
Founders'/ Directors' percentage	**24.1%**
Market Cap (A$0.75 share price)	**A$114.9M**
Cash (31 Dec 2025 Quarterly + R&D + Cap Raise)	**~A$22.8M**

Henk-Jan Boele, Co-founder
Managing Director & CEO

MD, PhD, Entrepreneur and Neuroscientist at Erasmus MC and Princeton University

Anton Uvarov, Co-founder
COO & Executive Director

MBA, PhD, Biotech Analyst with Citibank

Bas Koekkoek
Co-founder CSO

PhD, Assistant Prof. of Neuroscience, Erasmus MC

Peter Boele
Co-founder CTO

MA, Startup Entrepreneur, PhD Candidate at Erasmus MC

Brian Leedman
Non-Executive Chairman

Experienced Chairman and Co-Founder of Five ASX-listed Healthcare Companies

Richard Hopkins
Non-Executive Director

20+ Years in Corporate Leadership Roles with Public Biotechnology Companies

What is Autism?

“A neurodevelopmental condition that affects how the brain processes sensory information.”

Autism can impact:

- Social and emotional functioning
- Language and communication
- Sensory and motor development
- Behavior and interests

Autism: The facts and the challenges

Prevalence in children has grown to up to 3% in the US [1-3]



(1) Center for Disease and Control, World Health Organization; (2) Santomauro et al., (2025) The global epidemiology and health burden of the autism spectrum: findings from the Global Burden of Disease Study 2021, Lancet Psychiatry 2025; (3) Solmi et al., (2023) Incidence, prevalence, and global burden of autism spectrum disorder from 1990 to 2019 across 204 countries; Molecular Psychiatry;

Autism prevalence increases globally [4,5]



(4) Li et al., (2022) Epidemiology of autism spectrum disorders: Global burden of disease 2019 and bibliometric analysis of risk factors; Frontiers in Pediatrics; (5) https://worldpopulationreview.com/country-rankings/autism-rates-by-country

Autism healthcare costs are soaring [6,7]

- Economic burden of autism was **$700B** in 2024
- Costs for a diagnostic evaluation: **$1,000 to $7,000**
- Lifetime cost for individual with ASD: **$3.6M**

(6) Leigh and Du (2015), Forecasting the economic burden of autism in 2015 and 2025 in the US, Journal of Autism and Developmental Disorder; (7) Cakir et al. (2020) The lifetime social cost of autism: 1990-2029, Research in Autism Spectrum Disorder

Long waitlists and shortage of behavioral specialists [8]

- 800 specialists for **19M children** with developmental concerns
- Autism clinical evaluation time is between **3-8 hours**
- Average wait time for an autism assessment is over **2 years**

(8) March2023, https://cognoa.com/waitlist-crisis-report/

Autism diagnosis still lacks an objective medical test

*There is currently **no biomarker**, such as a blood test or brain scan, used in clinical practice.*

Diagnosis relies on behavioral assessments based on DSM-5 criteria, using questionnaires and clinician observations.



Over 100 autism questionnaires have been developed since 1969, yet no objective diagnostic test exists (no FDA approval)

Data extracted by BlinkLab from PubMed search.

Australia: NDIS payments for autism is over A$9.9B in 2025

Autism accounts for 41% of all NDIS participants, making it the most common disability.





Data extracted and visualized by BlinkLab, based on information from the National Disability Insurance Scheme (NDIS) - https://dataresearch.ndis.gov.au/reports-and-analyses/participant-dashboards/autism

Consensus: Early diagnosis and intervention helps children to develop crucial skills and reduces long-term support needs and costs

➢ Early detection and diagnosis is crucial [1-5]

The American Academy of Pediatrics recommends that all children must be screened for autism at ages 18 and 24 months.

Children born annually: US 3.6M, EU 3.7M, AU 296K

➢ Early intervention is cost-effective [6-12]

Every dollar spent on early treatment saves more than three dollars in future support costs by the time a child turns 13 (Segal, using NDIS data)[13].

Image from Southwest Autism Research & Resource Center's (SARRC), one of the sites participating in BlinkLab's 510(k) pivotal study

1.National Research Council, Committee on Educational Interventions for Children with Autism. *Educating Children With Autism*. Lord, C., McGee, J. P., eds. Washington, DC: National Academies Press; 2001.
2.Olley, J. G. (2005). Curriculum and classroom structure. In: Volkmar, F. R., Paul, R., Klin, A., Cohen, D. (Eds.), *Handbook of Autism and Pervasive Developmental Disorders*. 3rd ed. Vol II (863–881). Hoboken, NJ: John Wiley & Sons.
3.Helt, M., Kelley, E., Kinsbourne, M., Pandey, J., Boorstein, H., Herbert, M., et al. (2008). Can children with autism recover? If so, how? *Neuropsychology Review, 18*(4), 339–366.
4.Rogers, S. J., & Lewis, H. (1989). An effective day treatment model for young children with pervasive developmental disorders. *Journal of the American Academy of Child and Adolescent Psychiatry, 28*(2), 207–214.
5.Reichow, B., & Wolery, M. (2009). Comprehensive synthesis of early intensive behavioral interventions for young children with autism based on the UCLA young autism project model. *Journal of Autism and Developmental Disorders, 39*(1), 23–41.
6.Pye K, Jackson H, Iacono T, Shiell A. Economic Evaluation of Early Interventions for Autistic Children: A Scoping Review. J Autism Dev Disord. 2024 May;54(5):1691-1711.
7.Tinelli M, Roddy A, Knapp M, et al. Economic analysis of early intervention for autistic children: findings from four case studies in England, Ireland, Italy, and Spain. *European Psychiatry*. 2023;66(1):e76.
8.Hope For Three. (2025). Understanding the High Costs of Autism Care.
9.University of California. (2015). Autism's costs estimated to be $500 billion, potentially $1 trillion, by 2025. ScienceDirect. (2020).
10. The lifetime social cost of autism: 1990- 2029.
11. Above and Beyond Therapy. (2025). How Much ABA Therapy Really Costs with Insurance.
12. Cross River Therapy. (2025). ABA Therapy Insurance Coverage for Autism (By State).
13.Preemptive therapy prior to autism diagnosis may be highly cost-effective, article originally appeared in Autism Research Review International, Vol. *37, No. 2, 2023, by* Leonie Segal

AUTISM RESEARCH INSTITUTE

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN®


BlinkLab’s AI-enabled
Smartphone-based Assessment
blinklab

Our patented solution: Neuroscience on a smartphone

Minuscule facial reflexes, evoked by our app, generate a digital biomarker for autism.

Evokes Facial Reflexes

By presenting visual and auditory stimuli during smartphone use.

Computer Vision

Facial features are tracked on the smartphone and transferred to the **BlinkLab platform**.

Biomarker Detection

Biomarkers are detected in **real-time** and made available to the clinician.

Evaluates brain function

State-of-the art analysis methods and AI modelling to **map the functioning of brain regions involved in autism**.

Patents: PCT/US2021/058698; US 18/036,009; Europe 21892692; Japan 2023-528017; Canada 3,195,596; Korea 10-2023-7018839; Australia 2021378273; US Provisional 63/218,607; 63/460,451; 63/548,542

High-Profile Journal Publication Validates BlinkLab's Technology and Provides Support for Future Clinical Adoption

Neurobehavioral Assessment of Sensorimotor Function in Autism Using Smartphone Technology

Kayleigh D. Gultig[1,2] | Cornelis P. Boele[2] | Lotte E. M. Roggeveen[2] | Ting Fang Soong[2] | Seth Sherry[2,3] | Caroline Jung[3] | Sara Milosevska[1] | Anton Uvarov[2] | Khalid Benhassan[4] | Said Ait BenAli[5] | Yasmine Ahajoui[6] | Valeria Carpio-Arias[7] | Sander Lindeman[2] | Sebastiaan K. E. Koekkoek[2] | Esra Sefik[3] | Myrthe J. Ottenhoff[2] | Samuel S.-H. Wang[3] | Chris I. De Zeeuw[1,8] | Abdeslem El Idrissi[9] | Henk-Jan Boele[1,2,3]

[1]Department of Neuroscience, Erasmus MC, Rotterdam, the Netherlands | [2]BlinkLab Limited, Perth, Australia | [3]Neuroscience Institute, Princeton University, Princeton, New Jersey, USA | [4]Mohammed VI National Center for the Disabled, Salé, Morocco | [5]Department of Neurosurgery, Cadi Ayyad University, Mohammed VI University Hospital Center, Morocco | [6]Department of Psychology, FLSHM—Hassan II University, Casablanca, Morocco | [7]Escuela Superior Politécnica de Chimborazo, Facultad de Salud Pública, Riobamba, Ecuador | [8]Netherlands Institute for Neuroscience, Royal Academy of Arts and Sciences, Amsterdam, the Netherlands | [9]Center for Developmental Neuroscience, City University of New York, College of Staten Island, New York, USA

Correspondence: Henk-Jan Boele (hboele@princeton.edu) | Abdeslem El Idrissi (abdeslem.elidrissi@csi.cuny.edu)

Received: 1 July 2025 | **Revised:** 30 October 2025 | **Accepted:** 10 December 2025

RESEARCH ARTICLE OPEN ACCESS

Beyond blinks: Tracking of vocal responses and hand/head movements as objective markers for autism

Screen avoidance



Head rotations





Image used with permission

Side eye



Pupil range



Postural stability



Headphone touches



Mouth openings



Vocalizations



ASX Announcement – 5 January 2026 – High-profile journal publication validates BB1 technology
Research Article Link: https://onlinelibrary.wiley.com/doi/10.1002/aur.70166?af=R

Pilot Study Confirms High Diagnostic Accuracy and Readiness for FDA Trial

ASX Announcement 22 October 2025

Highlights:

- **Pilot Study Completion:** BlinkLab has successfully completed its U.S. Pilot Study of the Dx 1 diagnostic device, involving **485 children**.

- **Strong Diagnostic Performance:** Across a clinically diverse population representing the full spectrum of developmental concerns, BlinkLab Dx 1 achieved **83.7%** sensitivity and **84.7%** specificity relative to clinical reference diagnosis.

- **Performance Exceeds FDA Benchmark for Registrational Study:** In a formal meeting with the U.S. FDA on 16 October 2025, the agency agreed with BlinkLab's pivotal 510(k) study design and confirmed a minimum performance **threshold of >65%** sensitivity and **>65%** specificity for regulatory clearance. Based on FDA feedback, the main study has been refined to enroll approximately **528 participants** across leading U.S. autism research centres, streamlining timelines and reducing cost.

Why not 100% sensitivity and 100% specificity?

*The performance ceiling for BlinkLab Dx1 is **85-90%** due to diagnostic ambiguity and autism heterogeneity.*

➢ Diagnostic Stability

Autism clinical diagnostic stability is estimated around 80-90% stability. [1–5]



➢ Expert Consensus

Autism expert consensus is estimated around 70-80% accuracy. [6– 8]

If ground truth is not 100%, a digital biomarker trained on that label can't be 100% either.

[1] Elias et al. (2022). *Diagnostic stability in individuals with autism spectrum disorder: Insights from a longitudinal follow-up study.*

[2] May et al. (2021). *Parent-reported autism diagnostic stability and trajectories in the Longitudinal Study of Australian Children.*

[3] Pierce et al. (2019). *Evaluation of the diagnostic stability of the early autism spectrum disorder phenotype in the generalpopulation starting at 12 months.*

[4] Chawarska et al. (2009). *A prospective study of toddlers with ASD: Short-term diagnostic and cognitive outcomes.*

[5] Lord et al. (2006). *Autism from 2 to 9 years of age.*

[6] Esler et al. (2015). *The Autism Diagnostic Observation Schedule, Toddler Module: Standardized severity scores.*

[7] Mazefsky et al. (2013). *Comparability of DSM-IV and DSM-5 ASD research samples.*

[8] de Bildt et al. (2013). *How to use the ADI-R for classifying autism spectrum disorders?*

BlinkLab Outperforms FDA-approved Digital Peers

We are leaders in the digital autism diagnostics space

	blinklab	cognoa	EarliTec Diagnostics Inc.
Sensitivity	84%	52%*	71%
Specificity	85%	19%*	81%
Smartphone-based	Yes	Yes	No
FDA approval	No - *510(k)*	Yes - *De Novo*	Yes - *510(k)*

* Calculated over all study completers (Cognoa's device yielded indeterminate results in 68% of cases)

Study Design and Timeline for 510(k) Regulatory Trial for Dx 1

Prospective, multicenter in US, double-blinded, within-subject comparison study.



Main study: N = 264 children with autism and N = 264 children without autism.

Q4 2024	- CRO assigned
	- IRB approval for Pilot Study
	- First pre-submission meeting with FDA
Q1 2025	- Onboarded two US clinical sites for initial study: PriMED and NorthShore Pediatrics
	- Compliant with HIPAA and 21 CRF parts 11, 820
	- Started data collection for Pilot Study
Q2 2025	- IRB approval for main 528-patient Pivotal Study
Q3 2025	- Onboarding clinical and research sites for Pivotal Study
Q4 2025	- Second pre-submission meeting with FDA
	- Release of results from 485 patient Pilot Study
Q1 2026	- Start Pivotal 510(k) Study
Q4 2026	- Completion Pivotal Study and submission to FDA
Q1 2027	- Outcome from FDA 510(k)

* completed

BlinkLab Commences Pivotal Validation Program for FDA 510(k) Submission: First Participant Enrolled



Ten Leading US Autism Centers will Participate in the 510(k) Pivotal Study

Perelman School of Medicine, University of Pennsylvania
Cincinnati Children's
SARRC Southwest Autism Research & Resource Center
Thompson Center for Autism & Neurodevelopment, University of Missouri
University of Nebraska Medical Center, Nebraska Medicine
Vanderbilt Kennedy Center for Excellence in Developmental Disabilities
Seattle Children's Hospital • Research • Foundation
Rush University Medical Center
Drexel University
University of Arkansas

Study execution led by CRO partner IQVIA-MCRA, building on strong pilot study. 510(k) FDA submission targeted by year-end 2026.

IQVIA

BlinkLab Dx1 is intended for use as a diagnostic aid for clinicians in the assessment of autism spectrum disorder in pediatric populations.

The system is prescribed by a qualified healthcare professional and enables the collection of behavioral and neurometric data via a smartphone-based application in a home or clinical setting. The acquired data are transmitted to the clinician. The device is not intended to function as a stand-alone diagnostic or self-diagnosis tool.

The clinician is responsible for interpretation and integration of the results within the overall clinical evaluation. BlinkLab Dx1 is designed to support, not replace, clinical judgment.

We are experts in science, AI, tech, and commercialization

Henk-Jan Boele, CEO

MD, PhD, Entrepreneur and neuroscientist at Erasmus MC and Princeton University

Fifteen years of experience in neurobehavioral testing with over 35 publications. Recipient of many prestigious awards. Team leader and inventor of BlinkLab.

Anton Uvarov, COO
Executive director

MBA, PhD, Biotechnology Analyst with Citibank

Cofounder of two biotechnology companies, developed therapeutics for neurodegenerative disorders. Both successfully IPO and publicly traded.

Bas Koekkoek, CSO

PhD, Assistant Professor of Neuroscience. Erasmus MC

Twenty-six years of experience in neurobehavioral testing with over 55 publications in IEEE and the field of neuroscience. An innovator in heart and soul. Cofounder of Neurasmus BV.

Peter Boele, CTO

MA, PhD candidate, Erasmus MC

Born to code, with over 20 years of experience in software development, both as developer as well as executive.

Our mission is to use neuroscience to improve the daily life of families with autism.

We are backed up by an expert advisory board

Company Chairman

Brian Leedman

Experienced Chairman and co-founder of five ASX listed healthcare companies including digital healthcare company ResApp Health, acquired by Pfizer for $180M in 2022.

Company Director

Richard Hopkins

Experienced bio-pharmaceutical executive with over 20 years in corporate leadership roles with public biotechnology companies.

Scientific advisor

Prof. Samuel Wang

Professor of Neuroscience at Princeton University and author of 2 bestselling books.

Scientific advisor

Prof. Chris De Zeeuw

Professor of Neuroscience at Erasmus MC and vice-director of the NIN (Netherlands Institute of Neuroscience).

Scientific advisor

Prof. Javier Medina

Professor in neuroscience at Baylor College of Medicine in Houston.

World leading scientists, strategic and commercial advisors.

Our AI technology detects autism and ADHD



BlinkLab precisely measures sensory sensitivity in people with autism and ADHD.

Catalysts and milestones for Dx1 (autism) and Dx2 (ADHD) models

News pipeline on updates our regulatory studies on autism and ADHD and new partnerships

BlinkLab Dx 1 – Autism Model	Calendar Year
Submit CE/MDR clearance	3Q 2026
Complete Pivotal Study (i.e. last patient tested)	4Q 2026
Submit Pivotal Study results to FDA	4Q 2026
Milestone: FDA responses on 510(k) clearance for Dx1	1Q 2027

BlinkLab Dx 2 – ADHD model	Calendar Year
Complete European ADHD Study	2Q 2026
Submit for CE/MDR clearance	3Q 2026
Onboarding clinical sites and study preparations	3Q 2026
Start Dx2 Pivotal Study (i.e. first patient tested)	1Q 2027
Complete Dx2 Pivotal Study (i.e. last patient tested)	3Q 2027
Submit Dx2 Pivotal Study results to FDA	4Q 2027
Milestone: FDA responses on 510(k) clearance for Dx 2	1Q 2028

Note: This news pipeline excludes updates from the ongoing European Adult Autism Study, the Australian Monash Magnet Study, and the European Dementia Study.

Commercialization Strategy Assuming FDA clearance

Strategy applies to Dx1 in the US market only.

Substantially lower cost than competing tools, enabled by fully automated testing that allows initial use without reimbursement and accelerates adoption.



(1) CDC Autism Data & Statistics; AAP Autism Screening Guidelines (Hyman et al., *Pediatrics*, 2020).

BlinkLab Selected for Morocco's Nationwide Government-Funded Autism Screening Program

- ✓ Roll-out in 3,000 centers to test 600,000 children annually.
- ✓ Large-scale adoption before proposed FDA clearance.
- ✓ Data ownership and intellectual property retained by BlinkLab.
- ✓ Regional and Middle East expansion.
- ✓ Fully funded by the Moroccan government.
- ✓ Commercial terms revisited after FDA clearance.





Sensorimotor biomarkers have been widely studied, but clinical adoption was limited by technical complexity



Over 9000 peer-reviewed studies across neuropsychiatric disorders.

BlinkLab platform expansion: New indications and use cases are guided by strong scientific foundation (see previous slide)

European ADHD Study

- **Collaborator:** Mental Care Group
- **Goal:** Develop BlinkLab Dx 2 - ADHD Model
- **Status:** Recruiting – release of 300 patient results proposed for Q2 CY2026

ASX Announcement, 30th Jul 2024;
BlinkLab Partners with Mental Care Group in Europe

Australian MAGNET Study

- **Collaborator:** Monash University
- **Goal:** Genotyping and deep behavioral phenotyping of autism and ADHD
- **Status:** Recruiting in the 1000-family study

ASX Announcement, 13th Nov 2024;
BB1 to Participate in Monash Uni Autism/ADHD MAGNET Project

European Dementia Study

- **Collaborator:** Erasmus University Medical Center
- **Goal:** Early neurometric markers for frontotemporal and Alzheimer's dementia
- **Status:** Recruiting

ASX Announcement, 5th Jun 2024;
BlinkLab signs Clinical Study Partnership with Erasmus MC

European Adult Autism Study

- **Collaborator:** Amsterdam University
- **Goal:** Exploring BlinkLab neurometrics in adults with autism
- **Status:** Recruiting in 200-participant study

ASX Announcement, 19th Mar 2025;
Blinklab Expands Autism Diagnostics into Adults

Intellectual property

Our patents prohibit other parties to conduct neurometric testing using mobile devices.

BlinkLab has consistently prioritized the development and protection of its intellectual property since its seed funding round in August 2021. Our capital investments sourced from seed investors, government funding, and industry sponsorships - have been primarily utilized for IP and software development.

We are represented by the US-based law firm, Meagher Emanuel Laks Goldberg & Liao, LLP, which ensures our IP protection. We have filed National Stage Applications for 2020-2021 patents across various jurisdictions including the United States, Japan, Canada, Australia, Korea, and the European Patent Office (EPO) in March 2023.

Our portfolio comprises patents filed both by Princeton University, under an exclusive license agreement, and BlinkLab itself. These patents range from systems for neurobehavioral testing to methods for measuring emotional engagement, all of which firmly establish our innovation and leadership in the field.

Patents filed by Princeton University, with an exclusive license agreement in place between Princeton University and BlinkLab:

- PCT application number PCT/US2021/058698 Filed November 10, 2021, entitled “System and Method for Remote Neurobehavioral Testing”
- US patent application number 18/036,009 Filed May 9, 2023, entitled “System and Method for Remote Neurobehavioral Testing”
- European patent application number 21892692.1 Filed March 31, 2023, entitled “System and Method for Remote Neurobehavioral Testing”
- Japanese patent application number 2023-528017 Filed May 10, 2023, entitled “System and Method for Remote Neurobehavioral Testing”
- Canadian patent application number 3,195,596 Filed April 13, 2023, entitled “System and Method for Remote Neurobehavioral Testing”
- Korean patent application number 10-2023-7018839 Filed June 2, 2023, entitled “System and Method for Remote Neurobehavioral Testing”
- Australian patent application number 2021378273 Filed May 23, 2023, entitled “System and Method for Remote Neurobehavioral Testing”

Patents filed by BlinkLab:

- US Provisional patent application number 63/218,607 Filed on November 30, 2022, entitled “Psychopharmacological System and Method Using Eyelid Tracking”
- US Provisional patent application number 63/460,451 Filed on April 19, 2023, entitled “Method And System For Measuring Emotional Engagement”
- US Provisional patent application number 63/548,542 Filed on February 1, 2024, entitled “System And method For Detecting Neurological Condition”

blinklab *ASX:BB1*

For further information please contact:

Henk-Jan Boele, MD, PhD

Cofounder and MD/CEO

henkjan@blinklab.org

M: +31 (0) 611 132 247

Brian Leedman

Non-Executive Chairman

brian@blinklab.org

M: +61 (0) 412 281 780

info@blinklab.org

@BlinkLab.App

@Blink_Lab

BlinkLab Limited (ASX:BB1)

@BlinkLab Ltd

@BlinkLab2193